Figure 2
Therapeutic potential of MitoQ for dextran sulfate sodium-induced colitis. (A) Experimental design for DSS-induced colitis in mice. 4% DSS was administered to WT mice from day 0 to day 7 followed by 1% of DSS for the duration of the experiment. Two groups of mice additionally received dTPP and MitoQ from day 7. (B) Body weight of mice was measured every 3 days and presented as a percentage of their initial weight, n = 5 mice per group. (C) Bloody stool score on the 10th day. (D) Lengths of the freshly removed colons were measured from rectum to ileocecal junction. (E) Representative distal colon sections stained with hematoxylin and eosin. The magnification is indicated. (F) Crypt damage. (G) Colitis score. For all samples, results are expressed as mean ±SE. n = 3, *P <0.001. DSS+dTPP, DSS with dTPP-treated mice; DSS+MitoQ, DSS with MitoQ-treated mice; NS, not significant; WT, control mice; WT+DSS, DSS-treated mice.